SELLAS: Late-Stage Biotech Approaches 2023 Approval With Solid Funding (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) has made significant strides towards the potential approval of its lead product, galinpepimut-S (GPS), a cancer immunotherapy targeting acute myeloid leukaemia (AML). The company recently announced that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for GPS, which is currently under review. The FDA's communication indicates that the agency is on track to make a decision by the end of 2023, which would mark a pivotal moment for SELLAS as it seeks to commercialise its innovative treatment. The market has responded positively, with SELLAS's shares reflecting increased investor confidence in the company's prospects.

Historically, SELLAS has positioned itself as a late-stage biotech firm focusing on immunotherapies for cancer. The company has been navigating the complex regulatory landscape while simultaneously managing its financial health. As of the latest financial disclosures, SELLAS reported a market capitalisation of approximately USD 45 million. The company has been proactive in securing funding to support its clinical development and operational activities, which is crucial as it approaches the final stages of the NDA process. Recent financing efforts have bolstered its cash reserves, providing a runway that is expected to sustain operations through the anticipated approval timeline.

In terms of financial position, SELLAS has successfully raised capital through various means, including public offerings and private placements. The most recent funding round raised USD 15 million, which is earmarked for advancing the clinical development of GPS and other pipeline candidates. With a quarterly burn rate of approximately USD 3 million, SELLAS has an estimated funding runway of five months, which aligns well with the FDA's review timeline. However, investors should remain vigilant regarding potential dilution risks associated with future capital raises, especially if the company needs to extend its funding beyond the current cash reserves.

Valuation metrics for SELLAS indicate that the company is trading at a relatively low enterprise value compared to its peers in the biotech sector. For instance, SELLAS's enterprise value (EV) is approximately USD 30 million, which translates to an EV per clinical asset of around USD 15 million. In comparison, peers such as Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and Zymeworks Inc. (NYSE:ZYME) are trading at EVs of USD 1.5 billion and USD 500 million, respectively, reflecting EV per clinical asset valuations of USD 150 million and USD 100 million. This stark contrast suggests that SELLAS may be undervalued relative to its potential, particularly if the FDA grants approval for GPS.

SELLAS's execution track record has been commendable, with the company meeting key milestones in its clinical development program. The NDA submission for GPS was a significant achievement, and the feedback from the FDA reinforces the company's strategic direction. However, the biotech sector is fraught with risks, particularly regulatory uncertainties. The primary risk for SELLAS at this juncture is the potential for the FDA to request additional data or impose conditions that could delay the approval process. Such outcomes could adversely affect investor sentiment and the company's market valuation.

Looking ahead, the next measurable catalyst for SELLAS will be the FDA's decision on the NDA for GPS, which is expected by December 2023. This timeline is critical, as it will determine the company's ability to commercialise its lead product and generate revenue. A positive decision could significantly enhance SELLAS's market position and attract further investment, while a negative outcome would likely lead to a reassessment of the company's prospects and valuation.

In conclusion, the recent announcement regarding the FDA's feedback on SELLAS's NDA for GPS is a significant development that enhances the company's prospects for approval and commercialisation. The financial position appears solid, with adequate funding to navigate the upcoming months, although dilution risks remain a concern. The valuation metrics suggest that SELLAS is undervalued relative to its peers, and the execution track record has been strong. Overall, this announcement can be classified as significant, as it materially impacts the company's valuation, risk profile, and execution outlook.

Key insights

• ●FDA decision on NDA expected by December 2023.
• ●Recent funding raised USD 15 million for clinical development.
• ●SELLAS's EV per clinical asset is USD 15 million, indicating undervaluation.

Disagree with this article?